UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000006086 |
|---|---|
| Receipt number | R000007037 |
| Scientific Title | Efficacy and safety of Eribulin as the first line therapy for advanced or recurrent breast cancer patients without HER2 overexpression. |
| Date of disclosure of the study information | 2011/07/31 |
| Last modified on | 2016/06/12 16:35:15 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2011/07/31 19:48:44 | ||
| 2 | Update | 2011/09/27 11:15:16 | Acronym Acronym |
|
| 3 | Update | 2011/09/27 11:15:49 | ||
| 4 | Update | 2012/03/06 12:57:02 | Organization1 Address1 Tel1 Email1 |
|
| 5 | Update | 2014/11/24 15:55:13 | Key inclusion criteria |
|
| 6 | Update | 2014/11/24 15:57:27 | Email Last name of contact person Last name of contact person Address |
|
| 7 | Update | 2014/11/24 16:00:44 | Recruitment status Last follow-up date |
|
| 8 | Update | 2016/06/12 16:35:15 | Recruitment status Last follow-up date Date of closure to data entry Date trial data considered complete Date analysis concluded Publication of results URL related to results and publications Results |
